These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33616993)

  • 1. Editorial: microbiome modulation by rifaximin in severe alcoholic hepatitis.
    Youn GS; Suk KT
    Aliment Pharmacol Ther; 2021 Feb; 53(4):561-562. PubMed ID: 33616993
    [No Abstract]   [Full Text] [Related]  

  • 2. Rifaximin for severe alcoholic hepatitis-Attractive but unfructuous.
    Giri S; Kasturi S; Darak H
    Liver Int; 2022 Jul; 42(7):1698-1699. PubMed ID: 35567764
    [No Abstract]   [Full Text] [Related]  

  • 3. Rifaximin prevents ethanol-induced liver injury in obese KK-A
    Kitagawa R; Kon K; Uchiyama A; Arai K; Yamashina S; Kuwahara-Arai K; Kirikae T; Ueno T; Ikejima K
    Am J Physiol Gastrointest Liver Physiol; 2019 Nov; 317(5):G707-G715. PubMed ID: 31509430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis.
    Kim SS; Eun JW; Cho HJ; Song DS; Kim CW; Kim YS; Lee SW; Kim YK; Yang J; Choi J; Yim HJ; Cheong JY
    Aliment Pharmacol Ther; 2021 Feb; 53(4):540-551. PubMed ID: 33264437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Disease, Dysbiosis, and Dyspepsia: How Helpful Is Rifaximin?
    Sundaram S; Darak H
    Dig Dis Sci; 2022 Jun; 67(6):1915-1916. PubMed ID: 34392457
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial.
    Kimer N; Meldgaard M; Hamberg O; Kronborg TM; Lund AM; Møller HJ; Bendtsen F; Ytting H
    PLoS One; 2022; 17(3):e0264278. PubMed ID: 35286322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial.
    Madsen BS; Trebicka J; Thiele M; Israelsen M; Arumugan M; Havelund T; Krag A
    Trials; 2018 Feb; 19(1):143. PubMed ID: 29482588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders--A Focus on the Modulation of Host Tissue Function.
    Hirota SA
    Mini Rev Med Chem; 2015; 16(3):206-17. PubMed ID: 26202186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
    Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of alcoholic liver disease.
    Singal AK; Jampana SC
    Curr Drug Abuse Rev; 2014; 7(1):18-28. PubMed ID: 25323125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central and Mucosal Immunities are Modified by Non Adsorbable Antibiotic Treatment in Uncomplicated Diverticular Disease.
    Pandolfi F; Frosali S; Petruzziello L; Newton EE; Costamagna G
    Mini Rev Med Chem; 2015; 16(3):218-21. PubMed ID: 26202195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Rifaximin in Inflammatory Bowel Disease Treatment.
    Scribano ML
    Mini Rev Med Chem; 2015; 16(3):225-9. PubMed ID: 26202194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
    Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
    Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    DuPont HL
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifaximin on intestinally-related pathologic changes in sickle cell disease.
    Dutta D; Li K; Methe B; Lim SH
    Am J Hematol; 2020 Apr; 95(4):E83-E86. PubMed ID: 31925798
    [No Abstract]   [Full Text] [Related]  

  • 18. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
    Bruzzese E; Pesce M; Sarnelli G; Guarino A
    Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.
    Dong T; Aronsohn A; Gautham Reddy K; Te HS
    Dig Dis Sci; 2016 Dec; 61(12):3621-3626. PubMed ID: 27655104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.